EN SV HOME INVESTORS INVESTMENT STORY Investment story With a solid financial position and significant potential in our portfolio of pre-market and on-market products, Sobi is well positioned for continued international expansion and strong growth in an attractive market. 0 SEK M Full year revenue 2020 0 SEK M EBITA 0 Number of employees Well positioned in a fundamentally attractive market Sobi is a global player in the fundamentally attractive market of rare diseases, which is characterised by high unmet medical needs. Rare disease therapies can generally command a higher price and have a shorter time to market than other pharmaceuticals. Rare disease therapies are also less likely to face generic competition, limiting price pressure. Significant pre-market pipeline Sobi has built a significant pre-market pipeline through the continued development of core assets and by acquiring promising late-stage assets. External growth is essential for the strategy and Sobi continues to evaluate opportunities. The mid-term focus is on the current premarket portfolio which has potential to offer significant organic growth opportunities. International expansion Sobi is present in more than 30 markets across Europe, North America, the Middle East, Russia, North Africa and Asia. There is significant potential to expand our global position, with focus on the 15 largest markets representing the major part of the global market for rare diseases. This would enable Sobi to maximise the growth potential of its pre-market and on-market portfolio. Commercial excellence is our core competence Our core competence is within late-stage clinical development and commercialisation, which opens up for co-development opportunities. Commercial excellence refers to our skills and experience, competence and networks required to launch innovative rare-disease and niche medicines for sustainable patient access. Cash flow and financial position support growth Sobi has a strong cash conversion, which has enabled investments in both on-market products and late-stage assets in the R&D portfolio as well as in focused bolt-on and transformational acquisitions. The ambition is to further strengthen cash flow and profitability of the commercial portfolio, and to drive development projects to market launch over the next five years. Sobi has good financial capacity based on a strong operational cash flow which enables debt-financed external growth followed by quick reduction of debt. About us At a glance Rare diseases Therapeutic areas Haematology Immunology Specialty Care portfolio Investors Reports & presentations Share information Calendar Career Open positions Meet our employees Media Press releases Gallery Sobiplay Sitemap Cookie Policy Privacy Policy Terms of use Cookies Settings © Swedish Orphan Biovitrum AB (publ) Reg. no. 556038-9321 This website uses cookies By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. Accept All Cookies Cookies Settings